A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod - Trial NCT05927415
Access comprehensive clinical trial information for NCT05927415 through Pure Global AI's free database. This Phase 1 trial is sponsored by argenx and is currently Not yet recruiting. The study focuses on Renal Impairment. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
NCT05927415
Phase 1
Not yet recruiting
biological
Trial Details
ClinicalTrials.gov • NCT05927415
View on ClinicalTrials.gov
A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod
A Phase 1, Open-label, Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10 mg/kg Single Dose Administered in Participants With Renal Impairment
Study Focus
Sponsor & Location
argenx
Timeline & Enrollment
Phase 1
Jul 10, 2023
Jul 01, 2024
48 participants
Primary Outcome
Efgartigimod PK parameters (Cmax)
Summary
A study to test how kidney problems influence the blood concentrations of efgartigimod
ICD-10 Classifications
Renal failure
Disorders resulting from impaired renal tubular function
Disorder resulting from impaired renal tubular function, unspecified
Other disorders resulting from impaired renal tubular function
Acute renal failure
Data Source
ClinicalTrials.gov
NCT05927415
Non-Device Trial